Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Cavo M; Pantani L; Petrucci MT; Patriarca F; Zamagni E; Donnarumma D; Crippa C; Boccadoro M; Perrone G; Falcone A; Nozzoli C; Zambello R; Masini L; Furlan A; Brioli A; Derudas D; Ballanti S; Dessanti ML; De Stefano V; Carrella AM; Marcatti M; Nozza A; Ferrara F; Callea V; Califano C; Pezzi A; Baraldi A; Grasso M; Musto P; Palumbo A

research article

oai:air.uniud.it:11390/870296

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Authors: Cavo M
Pantani L
Petrucci MT
Patriarca F
Zamagni E
Donnarumma D
Crippa C
Boccadoro M
Perrone G
Falcone A
Nozzoli C
Zambello R
Masini L
Furlan A
Brioli A
Derudas D
Ballanti S
Dessanti ML
De Stefano V
Carrella AM
Marcatti M
Nozza A
Ferrara F
Callea V
Califano C
Pezzi A
Baraldi A
Grasso M
Musto P
Palumbo A
Publication date: 1 January 2012
Publisher
Doi

Abstract

Abstract is not available.

info:eu-repo/semantics/article

Similar works

Full text

Archivio istituzionale della ricerca - Università degli Studi di Udine

oai:air.uniud.it:11390/870296

Last time updated on 12/11/2016

This paper was published in Archivio istituzionale della ricerca - Università degli Studi di Udine.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.